DongKook Pharmaceutical Valuation

Is A086450 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A086450 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A086450 (₩18400) is trading above our estimate of fair value (₩4766.95)

Significantly Below Fair Value: A086450 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A086450?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A086450. This is calculated by dividing A086450's market cap by their current preferred multiple.
What is A086450's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₩809.02b

A086450 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	8.9x
PEG Ratio	1x

Price to Earnings Ratio vs Peers

How does A086450's PE Ratio compare to its peers?

The above table shows the PE ratio for A086450 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	17.2x
A214370 Caregen	25.4x	14.1%	₩859.4b
A000640 Dong-A Socio Holdings	15.3x	n/a	₩782.6b
A001060 JW Pharmaceutical	19.2x	29.4%	₩675.1b
A003090 Daewoong	8.9x	n/a	₩1.1t
A086450 DongKook Pharmaceutical	14.8x	14.4%	₩809.0b

Price-To-Earnings vs Peers: A086450 is good value based on its Price-To-Earnings Ratio (14.8x) compared to the peer average (17.2x).

Price to Earnings Ratio vs Industry

How does A086450's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	38.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	38.2%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: A086450 is expensive based on its Price-To-Earnings Ratio (14.8x) compared to the KR Pharmaceuticals industry average (14.7x).

Price to Earnings Ratio vs Fair Ratio

What is A086450's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A086450 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	14.8x
Fair PE Ratio	18.5x

Price-To-Earnings vs Fair Ratio: A086450 is good value based on its Price-To-Earnings Ratio (14.8x) compared to the estimated Fair Price-To-Earnings Ratio (18.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.